Aardvark Therapeutics(AARD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AARD Aardvark Therapeutics

Market Closed 12-12 16:00:00 EST

14.43

-1.18

-7.56%

盘后14.38

-0.05-0.35%

16:45 EST

High15.97	Low14.27	Vol267.19K
Open15.97	D1 Closing15.61	Amplitude10.92%
Mkt Cap313.09M	Tradable Cap84.96M	Total Shares21.70M
T/O3.96M	T/O Rate4.54%	Tradable Shares5.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":14.43,"timestamp":1765573200000,"preClose":15.61,"halted":0,"volume":267186,"hourTrading":{"tag":"盘后","latestPrice":14.38,"preClose":14.43,"latestTime":"16:45 EST","volume":1857,"amount":26784.61,"timestamp":1765575931967},"delay":0,"floatShares":5888000,"shares":21696893,"eps":-0.648,"marketStatus":"Market Closed","change":-1.18,"latestTime":"12-12 16:00:00 EST","open":15.97,"high":15.97,"low":14.265,"amount":3957328.450482,"amplitude":0.109225,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.648,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":15.61,"preHourTrading":{"tag":"盘前","latestPrice":15.97,"preClose":15.61,"latestTime":"08:46 EST","volume":51,"amount":789.309966,"timestamp":1765547181190},"postHourTrading":{"tag":"盘后","latestPrice":14.38,"preClose":14.43,"latestTime":"16:45 EST","volume":1857,"amount":26784.61,"timestamp":1765575931967},"volumeRatio":0.9800782779217414},"requestUrl":"/m/hq/s/AARD/tweets","defaultTab":"tweets","newsList":[{"id":"2591804638","title":"Aardvark Therapeutics CEO Tien-Li Lee Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2591804638","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591804638?lang=en_us&edition=fundamental","pubTime":"2025-12-13 09:30","pubTimestamp":1765589442,"startTime":"0","endTime":"0","summary":"Tien-Li Lee, Chief Executive Officer and Director of Aardvark Therapeutics Inc., reported the acquisition of common shares of the company, according to a recent SEC filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251213:nNDLbRv6nH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aardvark Therapeutics CEO Tien-Li Lee Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2591686624","title":"Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2591686624","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591686624?lang=en_us&edition=fundamental","pubTime":"2025-12-13 03:04","pubTimestamp":1765566240,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics gains an Outperform rating as its Phase 3 PWS trial progresses and analysts point to large market potential for ARD-101 and ARD-201.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/12/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/12/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49371535/aardvarks-hunger-suppressing-drug-candidate-could-potentially-address-massive-10-billion-market-analyst","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49371535/aardvarks-hunger-suppressing-drug-candidate-could-potentially-address-massive-10-billion-market-analyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["PWS","AARD"],"gpt_icon":0},{"id":"2591141688","title":"Aardvark Therapeutics Initiated at Outperform by William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2591141688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591141688?lang=en_us&edition=fundamental","pubTime":"2025-12-13 00:37","pubTimestamp":1765557420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 11:37 ET (16:37 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2590091405","title":"William Blair Initiates Aardvark Therapeutics With Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590091405","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590091405?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:05","pubTimestamp":1765544745,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. (AARD) has an average rating of Buy and mean price target of $33.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD"],"gpt_icon":0},{"id":"2590558148","title":"Aardvark Therapeutics Doses First Patient in Phase 3 HERO Trial for Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590558148","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590558148?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400712,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. has announced the dosing of the first patient in Australia as part of its Phase 3 HERO pivotal clinical trial evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi syndrome . Regulatory clearance for trial enrollment has also been received in Canada and the United Kingdom, with enrollment already underway in the United States and Australia. The company reports strong interest and participation from the patient community, noting that all patients who have completed the 12-week trial to date have enrolled in the Open Label Extension trial. Aardvark anticipates topline data from the HERO trial will be available in Q3 2026. No results have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL1jtNCN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","AARD","IE00BGHQF748.EUR","SG9999014039.USD","BK4585","SG9999014005.SGD","BK4112","SG9999014013.SGD","NDAQ","LU0314104364.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4588","IE00BKPKM429.USD","LU2095319765.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2590558673","title":"Aardvark Therapeutics Announces First Patient Dosed in Australia in Hero Phase 3 Trial for Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590558673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590558673?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA7G2YTX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2590553397","title":"Aardvark Therapeutics Inc - Regulatory Clearance for Enrollment by Clinical Trial Sites in Canada and the UK Has Also Been Received","url":"https://stock-news.laohu8.com/highlight/detail?id=2590553397","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590553397?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA7G2YTX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2588104536","title":"Raymond James Initiates Aardvark Therapeutics at Strong Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588104536","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588104536?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:12","pubTimestamp":1764763966,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (AARD) has an average rating of buy and mean price target of $32.44, according to analysts polled by FactSet. Price Target(MT Newswires covers equity, commodity and economic rese","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD","LU1363072403.SGD","BK4588","LU1804176565.USD","RJF","LU2265009873.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4585","LU0971096721.USD","BK4127"],"gpt_icon":0},{"id":"2586409805","title":"Aardvark Therapeutics to Present at Upcoming Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2586409805","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586409805?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:05","pubTimestamp":1764104726,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. will present at the Piper Sandler 37th Annual Healthcare Conference in New York on Wednesday, December 3 at 8:00 a.m. ET, and at the Evercore ISI 8th Annual Healthcare Conference in Miami on Thursday, December 4 at 11:15 a.m. ET. Live webcasts of each presentation will be available on the company's website under the investors section.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL1Hpzy5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","EVR","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","BK4127","LU2210149790.SGD","IE00BGHQF748.EUR","BK4585","PIPR","IE00BKPKM429.USD","NDAQ","AARD","LU2210150020.SGD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2584009576","title":"Aardvark Therapeutics Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2584009576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584009576?lang=en_us&edition=fundamental","pubTime":"2025-11-18 12:07","pubTimestamp":1763438855,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. ( ($AARD) ) has released its Q3 earnings. Here is a breakdown of the information Aardvark Therapeutics, Inc. presented ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2583150015","title":"Aardvark Therapeutics Is Maintained at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2583150015","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583150015?lang=en_us&edition=fundamental","pubTime":"2025-11-14 23:47","pubTimestamp":1763135220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2025 10:47 ET (15:47 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2583509025","title":"Cantor Fitzgerald Reaffirms Their Buy Rating on Aardvark Therapeutics, Inc. (AARD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583509025","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583509025?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:36","pubTimestamp":1763127381,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Joshua Schimmer reiterated a Buy rating on Aardvark Therapeutics, Inc. yesterday and set a price target of $50.00. The co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-reaffirms-their-buy-rating-on-aardvark-therapeutics-inc-aard-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-reaffirms-their-buy-rating-on-aardvark-therapeutics-inc-aard-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2583054635","title":"BTIG Remains a Buy on Aardvark Therapeutics, Inc. (AARD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583054635","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583054635?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:35","pubTimestamp":1763123739,"startTime":"0","endTime":"0","summary":"BTIG analyst Jeet Mukherjee reiterated a Buy rating on Aardvark Therapeutics, Inc. today and set a price target of $26.00. Mukherjee covers the Hea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-remains-a-buy-on-aardvark-therapeutics-inc-aard-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-remains-a-buy-on-aardvark-therapeutics-inc-aard-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2583508647","title":"RBC Cuts Price Target on Aardvark Therapeutics to $18 From $19, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2583508647","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583508647?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:51","pubTimestamp":1763121085,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (AARD) has an average rating of buy and mean price target of $30.63, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD"],"gpt_icon":0},{"id":"2583512264","title":"Aardvark Therapeutics Q3 EPS $(0.75) Beats $(0.80) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583512264","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583512264?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:32","pubTimestamp":1763069550,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.80) by 6.72 percent. This is a 28.57 percent increase over losses of $(1.05) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48851385/aardvark-therapeutics-q3-eps-0-75-beats-0-80-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aardvark Therapeutics Q3 EPS $(0.75) Beats $(0.80) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2582390237","title":"Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582390237","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582390237?lang=en_us&edition=fundamental","pubTime":"2025-11-12 05:05","pubTimestamp":1762895100,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov.  11, 2025  (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/11/3185762/0/en/Aardvark-Therapeutics-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-C-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USAW.SI","LU2417539215.USD","LU0106831901.USD","LU0072461881.USD","LU0130517989.USD","BK4559","LU0980610538.SGD","TQQQ","AARD","MNQmain","LU0320765646.SGD","LU0162691827.USD","LU0052756011.USD","QID","LU0477156953.USD","NVIW.SI","TSYW.SI","LU2360032135.SGD","LU0310800965.SGD","LU1244550577.SGD","LU1791807156.HKD","LU1668664300.SGD","LU2236285917.USD","BK4207","LU0170899867.USD","BK4588","LU1162221912.USD",".IXIC","QLD","LU2462157665.USD","SQQQ","LU1244550221.USD","LU0130102774.USD","BK4585","LU0098860793.USD","LU2125154935.USD","IE00BSNM7G36.USD","USJW.SI","LU0648001328.SGD","LU1244550494.USD","LU2125154778.USD","BK4504","LU0128525689.USD","LU1267930227.SGD","BK4534","LU1201861249.SGD","BK4566","PSQ","NQmain"],"gpt_icon":1},{"id":"2581835427","title":"This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2581835427","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581835427?lang=en_us&edition=fundamental","pubTime":"2025-11-08 02:57","pubTimestamp":1762541820,"startTime":"0","endTime":"0","summary":"Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/07/Analyst-Woman-Working-With-Information-D.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/07/Analyst-Woman-Working-With-Information-D.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/11/48730325/this-aardvark-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-friday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/11/48730325/this-aardvark-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-friday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4112","AARD"],"gpt_icon":0},{"id":"2581888526","title":"Aardvark Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Price Target $26","url":"https://stock-news.laohu8.com/highlight/detail?id=2581888526","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581888526?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:57","pubTimestamp":1762520264,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nFWN3WJ214:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2581147004","title":"Aardvark Therapeutics Initiated at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2581147004","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581147004?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:40","pubTimestamp":1762515600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 06:40 ET (11:40 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2581798590","title":"Aardvark Therapeutics Showcases Obesity Research at ObesityWeek","url":"https://stock-news.laohu8.com/highlight/detail?id=2581798590","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581798590?lang=en_us&edition=fundamental","pubTime":"2025-11-05 06:17","pubTimestamp":1762294654,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. ( ($AARD) ) has issued an announcement. On November 4, 2025, Aardvark Therapeutics presented research at the ObesityWee...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-showcases-obesity-research-at-obesityweek?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-showcases-obesity-research-at-obesityweek?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://aardvarktherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0642},{"period":"1month","weight":0.3448},{"period":"3month","weight":0.6799},{"period":"6month","weight":0.3436},{"period":"1year","weight":-0.0981},{"period":"ytd","weight":-0.0981}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Aardvark Therapeutics","nameEN":"Aardvark Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aardvark Therapeutics(AARD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aardvark Therapeutics(AARD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aardvark Therapeutics,AARD,Aardvark Therapeutics股票,Aardvark Therapeutics股票老虎,Aardvark Therapeutics股票老虎国际,Aardvark Therapeutics行情,Aardvark Therapeutics股票行情,Aardvark Therapeutics股价,Aardvark Therapeutics股市,Aardvark Therapeutics股票价格,Aardvark Therapeutics股票交易,Aardvark Therapeutics股票购买,Aardvark Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aardvark Therapeutics(AARD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aardvark Therapeutics(AARD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction